Cost-effectiveness of MR-mammography in breast cancer screening of women with extremely dense breasts after two rounds of screening

• Verfasst von: Tollens, Fabian [VerfasserIn]
• Verfasst von: Baltzer, Pascal Andreas Thomas [VerfasserIn]
• Verfasst von: Dietzel, Matthias [VerfasserIn]
• Verfasst von: Schnitzer, Moritz L. [VerfasserIn]
• Verfasst von: Kunz, Wolfgang Gerhard [VerfasserIn]
• Verfasst von: Rink, Johann [VerfasserIn]
• Verfasst von: Rübenthaler, Johannes [VerfasserIn]
• Verfasst von: Froelich, Matthias F. [VerfasserIn]
• Verfasst von: Kaiser, Clemens G. [VerfasserIn]
• Titel: Cost-effectiveness of MR-mammography in breast cancer screening of women with extremely dense breasts after two rounds of screening
• Verf.angabe: Fabian Tollens, Pascal A.T. Baltzer, Matthias Dietzel, Moritz L. Schnitzer, Wolfgang G. Kunz, Johann Rink, Johannes Rübenthaler, Matthias F. Froelich and Clemens G. Kaiser
• E-Jahr: 2021
• Jahr: 09 September 2021
• Umfang: 8 S.
• Fussnoten: Gesehen am 26.10.2021
• Titel Quelle: Enthalten in: Frontiers in oncology
• Ort Quelle: Lausanne : Frontiers Media, 2011
• Jahr Quelle: 2021
• Band/Heft Quelle: 11(2021) vom: 9. Sept., Artikel-ID 724543, Seite 1-8
• ISSN Quelle: 2234-943X
• DOI: doi:10.3389/fonc.2021.724543
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1775326586
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

ObjectivesTo evaluate the cost-effectiveness of MR-mammography (MRM) vs. x-ray based mammography (XM) in two-yearly screening women of intermediate risk for breast cancer in the light of recent literature.MethodsDecision analysis and Markov modelling were used to compare cumulative costs (in US-$) and outcomes (in QALYs) of MRM vs. XM over the model runtime of 20 years. The perspective of the U.S. healthcare system was selected. Incremental cost-effectiveness ratios (ICER) were calculated and related to a willingness to pay-threshold of $ 100,000 per QALY in order to evaluate the cost-effectiveness. Deterministic and probabilistic sensitivity analyses were conducted to test the impact of variations of the input parameters. In particular, variations of the rate of false positive findings beyond the first screening round and their impact on cost-effectiveness were assessed.ResultsBreast cancer screening with MRM resulted in increased costs and superior effectiveness. Cumulative average costs of $ 6,081 per woman and cumulative effects of 15.12 QALYs were determined for MRM, whereas screening with XM resulted in costs of $ 5,810 and 15.10 QALYs, resulting in an ICER of $ 13,493 per QALY gained. When the specificity of MRM in the second and subsequent screening rounds was varied from 92% to 99%, the ICER resulted in a range from $ 38,849 to $ 5,062 per QALY.ConclusionsBased on most recent data on the diagnostic performance beyond the first screening round, MRM may remain the economically preferable alternative in screening women of intermediate risk for breast cancer due to their dense breast tissue.